Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 471.41K | 288.27K | 235.45K | 138.75K | 65.98K |
Gross Profit | 59.32K | 84.22K | -17.72K | -245.45K | 62.40K |
EBITDA | -1.04M | -1.22M | -811.47K | -4.05M | -4.11M |
Net Income | -1.15M | -1.64M | -917.58K | -5.32M | -4.98M |
Balance Sheet | |||||
Total Assets | 1.38M | 2.42M | 3.35M | 3.59M | 7.27M |
Cash, Cash Equivalents and Short-Term Investments | 66.08K | 818.16K | 1.41M | 1.34M | 306.51K |
Total Debt | 11.44K | 12.80K | 1.34M | 1.44M | 1.49M |
Total Liabilities | 545.61K | 470.72K | 1.89M | 2.16M | 3.38M |
Stockholders Equity | 834.81K | 1.95M | 1.47M | 1.43M | 3.89M |
Cash Flow | |||||
Free Cash Flow | -796.85K | -1.35M | -1.47M | -1.73M | -3.00M |
Operating Cash Flow | -796.85K | -1.33M | -1.47M | -1.68M | -2.39M |
Investing Cash Flow | 9.00K | 382.92K | 101.94K | -48.77K | -611.04K |
Financing Cash Flow | -1.95K | 539.10K | 1.35M | 2.77M | 783.92K |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
60 Neutral | C$6.88M | 181.82 | -3.45% | ― | 4.04% | 80.24% | |
53 Neutral | C$7.43M | ― | -112.06% | ― | 46.27% | 20.75% | |
51 Neutral | C$5.53M | 80.00 | 0.83% | ― | -8.84% | -96.82% | |
51 Neutral | $9.13M | ― | -63.75% | ― | 9.34% | 69.69% | |
46 Neutral | C$88.06M | ― | -971.43% | ― | 571.23% | 64.25% | |
46 Neutral | C$194.28M | -4.22 | -8.60% | 2.64% | 13.54% | -1.44% |
Blueberries Medical Corp. announced a C$1 million non-brokered private placement to fund and expand its operations. The offering is led by Terraflos Inc., which is exploring expansion in Latin America. This move is expected to enhance Blueberries’ operational capabilities and strengthen its market position in the medicinal cannabis industry.